Biotechnology Companies By Operating Margin
LargestBiggest EarnersMost ProfitableMost LiquidHighly LeveragedTop DividendsCapital-HeavyHighest ValuationLargest Workforce
Operating Margin
| Operating Margin | Efficiency | Market Risk | Exp Return | ||||
|---|---|---|---|---|---|---|---|
| 1 | BNOX | Bionomics Ltd ADR | 0.02 | 23.12 | 0.55 | ||
| 2 | QTTB | Q32 Bio | (0.13) | 4.83 | (0.64) | ||
| 3 | HALO | Halozyme Therapeutics | (0.09) | 3.83 | (0.36) | ||
| 4 | UTHR | United Therapeutics | 0.04 | 1.73 | 0.08 | ||
| 5 | ADAP | Adaptimmune Therapeutics Plc | (0.16) | 4.70 | (0.76) | ||
| 6 | GNFT | Genfit | 0.02 | 4.46 | 0.07 | ||
| 7 | MGNX | MacroGenics | 0.03 | 4.37 | 0.15 | ||
| 8 | XOMAP | XOMA Corp | 0.10 | 0.76 | 0.08 | ||
| 9 | XOMAO | XOMA Corporation | 0.07 | 0.39 | 0.03 | ||
| 10 | ALVO | Alvotech | 0.01 | 1.72 | 0.01 | ||
| 11 | ALVOW | Alvotech Warrant | 0.13 | 142.51 | 18.41 | ||
| 12 | GILD | Gilead Sciences | 0.19 | 1.42 | 0.27 | ||
| 13 | KRYS | Krystal Biotech | 0.02 | 2.45 | 0.04 | ||
| 14 | VRTX | Vertex Pharmaceuticals | (0.05) | 1.76 | (0.09) | ||
| 15 | MEIP | MEI Pharma | (0.05) | 2.51 | (0.13) | ||
| 16 | CPRX | Catalyst Pharmaceuticals | 0.09 | 1.93 | 0.17 | ||
| 17 | GMAB | Genmab AS | (0.28) | 1.52 | (0.42) | ||
| 18 | EXEL | Exelixis | 0.22 | 2.40 | 0.54 | ||
| 19 | REGN | Regeneron Pharmaceuticals | (0.40) | 1.73 | (0.70) | ||
| 20 | ADMA | ADMA Biologics | 0.10 | 4.74 | 0.48 |
The analysis above is based on a 90-day investment horizon and a default level of risk. Use the Portfolio Analyzer to fine-tune all your assumptions. Check your current assumptions here.
Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations. A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.